In a filing, ADMA Biologics Inc. revealed its Director KWON YOUNG acquired Company’s shares for reported $97500.0 on Aug 24. In the deal valued at $3.90 per share,25,000 shares were bought. As a result of this transaction, KWON YOUNG now holds 277,401 shares worth roughly $ 1.1 million.
Then, Fong Bryant sold 1,433,304 shares, generating $5,544,737 in total proceeds. Upon selling the shares at $3.87, the Director now owns 0 shares.
Before that, Grossman Adam S sold 250,000 shares. ADMA Biologics Inc. shares valued at $1,038,350 were divested by the President and CEO at a price of $4.15 per share. As a result of the transaction, Grossman Adam S now holds 2,273,085 shares, worth roughly $8.98 million.
PT values the company’s stock at a premium of 21.0 to its Friday closing price.
Price Performance Review of ADMA
On Friday, ADMA Biologics Inc. [NASDAQ:ADMA] saw its stock jump 2.07% to $3.95. On the same session, the stock had its day’s lowest price of $3.905, but rose to a high of $4.005. Over the last five days, the stock has lost -3.66%. ADMA Biologics Inc. shares have risen nearly 1.80% since the year began. Nevertheless, the stocks have risen 45.76% over the past one year. While a 52-week high of $4.65 was reached on 08/15/23, a 52-week low of $2.24 was recorded on 03/20/23. SMA at 50 days reached $3.91, while 200 days put it at $3.61. A total of 1.49 million shares were traded, compared to the trading of 3.51 million shares in the previous session.
Levels Of Support And Resistance For ADMA Stock
The 24-hour chart illustrates a support level at 3.90, which if violated will result in even more drops to 3.85. On the upside, there is a resistance level at 4.00. A further resistance level may holdings at 4.05. The Relative Strength Index (RSI) on the 14-day chart is 46.24, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.25, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 83.33%. Stochastics %K at 15.48% indicates the stock is a buying.
How much short interest is there in ADMA Biologics Inc.?
A steep rise in short interest was recorded in ADMA Biologics Inc. stocks on Aug 14, 2023, growing by 0.5 million shares to a total of 9.01 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 8.51 million shares. There was a rise of 5.55%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 4.20% of the overall stock float, the days-to-cover ratio (short ratio) rose to 3.84.
ADMA Biologics Inc. [ADMA] – Who Are The Largest Shareholders?
In filings from BlackRock Fund Advisors, it is revealed that the company now owns 14,813,612 shares, or roughly 6.67% of the outstanding ADMA shares. In other words, the investor’s shares have risen by 118,207 from its previous 13-F filing of 14695405.0. Additionally, The Vanguard Group, Inc. increased 5.43% of its stake after which the total value it holdings stand at $49,732,110. Over the last quarter, SSgA Funds Management, Inc. sold -2,474,686 shares of ADMA Biologics Inc., while Stonepine Capital Management LLC sold 1,131,631 shares. At present, D. E. Shaw & Co. LP is holding 8,173,817 shares valued at $33.92 million. Magnetar Financial LLC owned 6,035,538 shares of the company at the time of its most recent 13F filing, worth $25.05 million.
According to FactSet, ADMA Biologics Inc.’s share price will average $6.00 in the next year, based on opinions of analysts polled by the firm. This is up nearly 55.04 percent from its previous closing price of $3.87. Analysts expect ADMA Biologics Inc. stock to reach the higher price of $7.00, while the lowest price estimate is $5.00. However, 4 analysts have rated ADMA stock as a Buy in their predictions for 2023.